As Artificial Intelligence becomes more popular in everyday life, drug research and development companies are incorporating ...

Absci entered its new drug into Phase I trials in half the time and for many millions of dollars less than it would have cost ...

Clear Regulatory Path to Clinical Trials for Intranasal PTSD Therapy Targeting Multi-Billion-Dollar MarketSARASOTA, FL, May ...

Valinor Discovery, a company pioneering machine learning-powered simulation of therapeutic performance to derisk drug development, today exited stealth to announce their mission to train the first ...

When it comes to training artificial intelligence, OpenAI and Babylon Biosciences have shown that experienced hands can help ...

Conflicting QSSD definitions from two federal agencies mean that CMS’ administrative authority on drug pricing and payment is ...

A study published in the Journal of Medicinal Chemistry presents a new family of candidate compounds for the treatment of ...

Elliott is a very successful and astute activist investor. The firm's team includes analysts from leading tech private eq ...

MPox is endemic in DRC, and has continued to cause large numbers of cases in the WHO African Region. In April, 2025, the WHO has restated that MPox continues to be a Public Health Emergency of ...

A $1.25 million investment is driving the development of a new treatment for advanced and therapy-resistant prostate cancer ...

Slow progress, pipeline uncertainty & lack of catalysts weigh despite strong cash. Click to read why KYMR stock is a Hold.

Therini Bio anticipates using the proceeds to fund Phase 1b trials evaluating its lead candidate, THN391, for the treatment of Alzheimer’s Disease (AD) and Diabetic Macular Edema (DME), as well as ...